Glucagon antagonism as a potential therapeutic target in type 2 diabetes

J I Bagger; F K Knop; J J Holst; T Vilsbøll

doi:10.1111/j.1463-1326.2011.01427.x

Glucagon antagonism as a potential therapeutic target in type 2 diabetes

J I Bagger, F K Knop, J J Holst, T Vilsbøll

115 Citationer (Scopus)

Abstract

Glucagon is a hormone secreted from the alpha cells of the pancreatic islets. Through its effect on hepatic glucose production (HGP), glucagon plays a central role in the regulation of glucose homeostasis. In patients with type 2 diabetes mellitus (T2DM), abnormal regulation of glucagon secretion has been implicated in the development of fasting and postprandial hyperglycaemia. Therefore, new therapeutic agents based on antagonizing glucagon action, and hence blockade of glucagon-induced HGP, could be effective in lowering both fasting and postprandial hyperglycaemia in patients with T2DM. This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality.

Originalsprog	Engelsk
Tidsskrift	Diabetes, Obesity and Metabolism
Vol/bind	13
Udgave nummer	11
Sider (fra-til)	965-71
Antal sider	7
ISSN	1462-8902
DOI	https://doi.org/10.1111/j.1463-1326.2011.01427.x
Status	Udgivet - 2011

Adgang til dokumentet

10.1111/j.1463-1326.2011.01427.x

Citationsformater

@article{6bc622d86e6a4f8794b656d8af71d7fb,

title = "Glucagon antagonism as a potential therapeutic target in type 2 diabetes",

abstract = "Glucagon is a hormone secreted from the alpha cells of the pancreatic islets. Through its effect on hepatic glucose production (HGP), glucagon plays a central role in the regulation of glucose homeostasis. In patients with type 2 diabetes mellitus (T2DM), abnormal regulation of glucagon secretion has been implicated in the development of fasting and postprandial hyperglycaemia. Therefore, new therapeutic agents based on antagonizing glucagon action, and hence blockade of glucagon-induced HGP, could be effective in lowering both fasting and postprandial hyperglycaemia in patients with T2DM. This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality.",

keywords = "Biphenyl Compounds, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucagon-Secreting Cells, Humans, Hyperglycemia, Hypoglycemic Agents, Liver, Receptors, Glucagon, Signal Transduction",

author = "Bagger, {J I} and Knop, {F K} and Holst, {J J} and T Vilsb{\o}ll",

note = "{\textcopyright} 2011 Blackwell Publishing Ltd.",

year = "2011",

doi = "10.1111/j.1463-1326.2011.01427.x",

language = "English",

volume = "13",

pages = "965--71",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "11",

}

TY - JOUR

T1 - Glucagon antagonism as a potential therapeutic target in type 2 diabetes

AU - Bagger, J I

AU - Knop, F K

AU - Holst, J J

AU - Vilsbøll, T

PY - 2011

Y1 - 2011

N2 - Glucagon is a hormone secreted from the alpha cells of the pancreatic islets. Through its effect on hepatic glucose production (HGP), glucagon plays a central role in the regulation of glucose homeostasis. In patients with type 2 diabetes mellitus (T2DM), abnormal regulation of glucagon secretion has been implicated in the development of fasting and postprandial hyperglycaemia. Therefore, new therapeutic agents based on antagonizing glucagon action, and hence blockade of glucagon-induced HGP, could be effective in lowering both fasting and postprandial hyperglycaemia in patients with T2DM. This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality.

AB - Glucagon is a hormone secreted from the alpha cells of the pancreatic islets. Through its effect on hepatic glucose production (HGP), glucagon plays a central role in the regulation of glucose homeostasis. In patients with type 2 diabetes mellitus (T2DM), abnormal regulation of glucagon secretion has been implicated in the development of fasting and postprandial hyperglycaemia. Therefore, new therapeutic agents based on antagonizing glucagon action, and hence blockade of glucagon-induced HGP, could be effective in lowering both fasting and postprandial hyperglycaemia in patients with T2DM. This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality.

KW - Biphenyl Compounds

KW - Diabetes Mellitus, Type 2

KW - Fasting

KW - Glucagon

KW - Glucagon-Secreting Cells

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Liver

KW - Receptors, Glucagon

KW - Signal Transduction

U2 - 10.1111/j.1463-1326.2011.01427.x

DO - 10.1111/j.1463-1326.2011.01427.x

M3 - Journal article

C2 - 21615669

SN - 1462-8902

VL - 13

SP - 965

EP - 971

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 11

ER -

Glucagon antagonism as a potential therapeutic target in type 2 diabetes

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater